SIMULTANEOUS TWO PHOTON INDUCED PHOTODYNAMIC THERAPY

同时进行两个光子诱导光动力治疗

• 批准号: 2650190
• 负责人: H CRAIG DEES
• 金额: $ 9.99万
• 依托单位: PHOTOGEN, INC.
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-04-01 至 1998-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2650190
• 关键词: biomedical equipment development; clinical biomedical equipment; electromagnetic radiation; method development; neoplasm /cancer photoradiation therapy; photochemistry; photosensitizing agents; porphyrins; psoralens

DESCRIPTION: Photodynamic therapy (PDT) is a minimally-invasive technique whose usefulness in treating tumors has been limited by the inability of short wavelength light (e.g., usually ultraviolet) to deeply penetrate into tissue. Two-photon laser-induced PDT is proposed which will improve the depth of penetration into soft tissue and provide precise spatial control. Two-photon excitation will be effected using a mode-locked titanium-sapphire laser (76 MHZ pulse repetition rate) that produces near-infrared light (NIR) capable of stimulating photochemical reactions as a result of its extremely short pulse width (approximately 200 fs). Two near-infrared photons arrive simultaneously where the laser has been focused, allowing photochemical reactions to occur which normally require ultraviolet light. Therefore, development of new PDT agents for use with NIR light is not required to achieve the benefits of NIR activation. The applicants have recently shown that two-photon induced photochemistry can be used to kill bacteria and breast cancer cells in vitro. In this Phase I study, they propose to determine the two-photon light dose and time required to produce photodynamic therapy in vivo using laboratory mice treated with psoralen or Photofrin. The commercial applications are numerous. The improved PDT system offers new therapies for cancer without the debilitating side effects associated with surgery, ionizing radiation or chemotherapy. This system offers improved safety when compared to single-photon medical laser applications including non-photodynamic laser therapies for dermabrasion, retinal repair, tissue ablation and removal of arterial blockage. PROPOSED COMMERCIAL APPLICATION: Not available.

描述：光动力疗法（PDT）是一种微不足道的 其在治疗肿瘤方面有用的技术受到了限制 短波长光（例如，通常紫外线）无法 深入渗透到组织中。 提出了两光子激光诱导的PDT 这将改善渗透到软组织的深度并提供 精确的空间控制。将使用两光子激发 模式锁定的钛sapphire激光器（76 MHz脉冲重复率） 产生能够刺激的近红外光（NIR） 由于其极短的脉冲宽度，光化学反应 （大约200 fs）。 两个近红外光子同时到达 激光聚焦的地方，允许光化学反应 通常需要紫外线。 因此，发展 不需要与Nir Light一起使用的新PDT代理 NIR激活的好处。 申请人最近表明 两光子诱导的光化学可用于杀死细菌和 体外乳腺癌细胞。 在这个阶段我的研究中，他们建议 确定产生的两光子光剂量和时间 使用牛cor骨治疗的实验室小鼠在体内的光动力疗法 或光蛋白。 商业应用很多。 改进 PDT系统为癌症提供新的疗法，而无需使人衰弱 与手术，电离辐射或化学疗法相关的影响。 与单光子相比，该系统提供了改进的安全性 医疗激光应用，包括非体动力激光疗法 用于皮肤化，视网膜修复，组织消融和去除 动脉阻塞。 拟议的商业应用：不可用。